Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

11 evidence topics · 11 sources

Summary: limitations of current therapies

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.